Caribou Biosciences, Inc. CRBU
Caribou Biosciences, Inc. (Nasdaq: CRBU) is an oncology drug developer. Its lead program, vispacabtagene regedleucel (vispa-cel, CB-010), is in Phase 1 for relapsed/refractory B cell non-Hodgkin lymphoma (2L LBCL).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| vispa-cel (allogeneic anti-CD19 CAR-T) | r/r B-NHL / 2L LBCL | cell therapy | Phase 1 |
| CB-011 (allogeneic anti-BCMA CAR-T) | r/r multiple myeloma | cell therapy | Phase 1 |
Recent results and decisions
- Oct 6, 2026discontinued Caribou plans to discontinue development of vispa-cel (pivotal-trial ready, FDA alignment on Phase 3 design) citing the financing environment, and will evaluate strategic alternatives.
Caribou plans to discontinue vispa-cel and CB-011 allogeneic CAR-T cell therapy programs
Filing - Oct 6, 2026discontinued Caribou plans to discontinue development of CB-011 alongside a substantial workforce reduction; cash was $113.8 million at June 30, 2026.
Caribou plans to discontinue vispa-cel and CB-011 allogeneic CAR-T cell therapy programs
Filing - Oct 6, 2026n/a CFO Sriram Ryali's employment will terminate upon execution of a binding definitive agreement for a strategic alternative.
The employment of Sriram Ryali, the Company's Chief Financial Officer, will terminate on the date the Company executes a binding definitive agreement for a strategic alternative.
Filing
6 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 oncology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.